Evaluation of therapeutic efficiency of laparoscopic radical nephrectomy and postoperative immunotherapy with different doses of IL-2

Abstract

Abstract: AIM: To evaluate the therapeutic efficiency of laparoscopic radical nephrectomy and postoperative immunotherapy with different doses of IL-2. METHODS: A total of 38 patients underwent laparoscopic radical nephrectomy were enrolled. There were 33 patients with clear cell carcinoma, 2 patients with papillary renal cell carcinoma and 3 patients with granular cell carcinoma. Operative time, intraoperative bleeding, recovery time of gastrointestinal function, remove time of drainage tube, average hospital stay after operation and postoperative complications were investigated. All patients were divided into two groups according to postoperative immunotherapy with different doses of IL-2: group 1 (18 mL U/m²) and group 2 (1 mL U/m²). The therapeutic efficiency and the adverse reactions between groups were also been compared.RESULTS: A total of 38 patients underwent laparoscopic radical nephrectomy were enrolled. There were 33 patients with clear cell carcinoma, 2 patients with papillary renal cell carcinoma and 3 patients with granular cell carcinoma. Operative time, intraoperative bleeding, recovery time of gastrointestinal function, remove time of drainage tube, average hospital stay after operation and postoperative complications were investigated. All patients were divided into two groups according to postoperative immunotherapy with different doses of IL-2: group 1 (18 mL U/m²) and group 2 (1 mL U/m²). The therapeutic efficiency and the adverse reactions between groups were also been compared.CONCLUSION: Laparoscopic radical nephrectomy is safe, effective and fewer complications. Postoperative IL-2 immunotherapy can effectively delay recurrence and distant metastasis of renal cell carcinoma. The therapeutic efficiency of postoperative immunotherapy with low-dose trial of IL-2 is similar to high-dose trial of IL-2.

Key words: renal cell carcinoma, laparoscopic surgery, retroperitoneal approach, radical nephrectomy, Interleukin-2(IL-2)

CLC Number:

PAN Cai-ming, HUANG Hou-bao, QIU Cheng. Evaluation of therapeutic efficiency of laparoscopic radical nephrectomy and postoperative immunotherapy with different doses of IL-2[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 926-930.

References 15

[1]	Romo de Vivar Chavez A, de Vera ME, Liang X, et al. The biology of interleukin-2efficacy in the treatment of patients with renal cell carcinoma[J].Med Oncol,2009,26(Suppl 1):3-12.
[2]	王希路,胡海龙,吴长利.不同剂量白介素-2在局部进展性肾癌术后免疫治疗中的疗效评价[J].天津医药,2010,38(9):816-817.
[3]	杨江根,张秩序,方烈奎.经腹腹腔镜肾癌根治术(附82例报告)[J].现代泌尿外科生殖肿瘤杂志,2009,1(4):210-212.
[4]	毕晓芳,王春晖,史云强,等.后腹腔镜肾癌根治术经验总结及体会[J].中国医学创新,2013,10(18):13-15.
[5]	吴阶平. 泌尿外科学(上卷)[M].济南:山东科学技术出版社,2013:921-913.
[6]	李前跃,王砺,李志昆,等.后腹腔镜下肾癌根治术65例临床疗效分析[J].中华腔镜泌尿外科杂志,2012,6(1):17-19.
[7]	Desai MM,Strzemepkowski,MATIN SF,et al.Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy[J].J Urol,2005,173(1):38-41.
[8]	Albqami N,Janetschek G.Indicatications for the use of laparoscopic radical nephrectomy[J].Nat Clin Pract Urol,2006,3(1):32-37.
[9]	Mattar K,Finelli A,Expanding the indications for laparoscopic radical nephrectomy[J].Curr Opin Urol,2007,17(2):88-92.
[10]	左毅刚,丁明霞,王剑松,等.腹腔镜泌尿外科手术中建立后腹膜腔方法的技术改进[J].中国内镜杂志,2008,14(8):17-19.
[11]	Stolzenburg JU,Kallidonis P,Hellawell G,et al.Technique of larparoscopic endoscopic single site surgery radical nephrectomy[J].Eur Urol,2009,56:644-650.
[12]	张旭,王超,马鑫,等.后腹腔镜下根治性肾切除术及其应用解剖学研究[J].中华泌尿外科杂志,2008,29(9):584-587.
[13]	徐洪,张华,刘青峰,等.后腹腔镜下肾脏切除术的应用效果观察[J].山东医药,2011,51(2):80-81.
[14]	闫东,袁超应.肾癌术后的生物免疫治疗新进展[J]. 现代泌尿外科杂志,2012,17(4):422-424.
[15]	郑建华,杜君,陈旭升,等.肾癌受辅助性免疫治疗临床疗效评价[J].2012,39(2):97-100.